Alignment Verdict
Strongly AlignedSummary
Odyssey Therapeutics, Inc. (ODTX) is led by founder and CEO Gary D. Glick, Ph.D., a highly successful serial biotech entrepreneur, alongside CFO Jason Haas and COO Julie Clauss. The leadership team is heavily stacked with veteran drug hunters and developers. Glick has a proven track record of creating massive shareholder value in previous ventures, such as IFM Therapeutics, making his leadership a major draw for retail investors.
Management is strongly aligned with long-term shareholder value. While Glick’s direct equity stake sits at roughly 0.88%, his compensation is almost entirely equity-based, directly tying his payout to stock performance. The company recently completed a successful IPO in May 2026, which saw open-market insider buying from the newly minted CFO and continued backing from major venture capital syndicates subject to 180-day lock-ups. Investors get a proven founder-operator and a high-pedigree management team with meaningful skin in the game.
Detailed Analysis
Odyssey Therapeutics is led by Founder, President, and CEO Gary D. Glick, Ph.D., who launched the company in 2021. Glick is a serial biotech entrepreneur who previously founded Lycera, FirstWave Bio, IFM Therapeutics, and Scorpion Therapeutics. He is joined by Chief Financial Officer Jason Haas, who was hired in January 2025 from Syros Pharmaceuticals (where he was also CFO) with a mandate to steer the company's financial strategy toward its May 2026 initial public offering. Julie Clauss joined as Chief Operating Officer in April 2024 to align functions and enhance operational efficiency. Finally, Anthony Opipari, M.D., Ph.D., serves as Interim Chief Medical Officer and EVP of Translational Medicine; he is a trusted associate of Glick who co-founded several of his previous ventures.
Gary D. Glick, Ph.D., is the principal founder of Odyssey Therapeutics and remains highly active as the President, CEO, and a member of the board of directors. Some financial databases also list David Pompliano, Ph.D., as an early co-founder; however, Pompliano does not currently serve on the executive team or the board of directors, and the specific reason for his departure or his current whereabouts are unable to be verified. The company was incubated by Glick alongside a Scientific Advisory Board composed of prominent immunology researchers who continue to guide the company's clinical direction.
According to the company's S-1 registration document filed with the SEC, CEO Gary Glick directly owns 0.88% of the company's outstanding shares. While this is a somewhat modest percentage for a founder, it is standard for capital-intensive biotechs that have undergone massive private funding rounds. As a collective, management and the board oversee substantial stakes, with venture capital backers like SR One holding roughly 8.0% of shares. Glick's total compensation in 2025 was $5.25 million. Of this, his base salary was roughly $558,900 (about 10.6%), with the vast majority coming from stock options. In the pre-revenue biotech industry, compensation is typically tied to long-term clinical milestones and share price appreciation through options, rather than short-term financial metrics like annual revenue or one-year EPS. CFO Jason Haas earned roughly $1.48 million in 2025.
Because Odyssey Therapeutics just went public in May 2026, there is limited historical open-market insider trading over the last 12–24 months. However, the recent pattern points entirely to net buying. Several major insiders and existing venture capital backers purchased additional shares concurrently with the IPO. Furthermore, shortly after the stock began trading, CFO Jason Haas opportunistically purchased 1,000 shares on the open market at $20.00 per share (a $20,000 investment). There has been no significant insider selling, as executives and early investors are restricted from selling by standard 180-day lock-up agreements.
There are no known SEC investigations, accounting restatements, lawsuits, or public controversies involving the current executive team. The only notable C-suite event was the departure of former Chief Medical Officer Jeremy Sokolove, M.D. He joined Odyssey in 2023 to guide its pipeline into the clinic but departed in late 2025 to become a CMO In-Residence at Roivant Sciences (and later CMO of Vor Bio). While the departure appeared amicable and his position was quickly filled on an interim basis by Anthony Opipari, high-profile turnover in the clinical leadership role shortly before an IPO is a minor detail investors should monitor.
The management team has an exceptional track record of raising and allocating capital. Since 2021, Glick and his team raised over $500 million in private markets (including a $213 million Series D in 2025) and executed an upsized IPO that grossed over $300 million in May 2026. The team has efficiently used this capital to rapidly advance its pipeline, pushing its lead candidate (OD-001) into Phase 2a trials for ulcerative colitis. Historically, Glick has proven to be an elite capital allocator; at his previous company, IFM Therapeutics, he successfully guided multiple programs from ideation to clinical development and orchestrated asset sales to Bristol Myers Squibb (valued at over $2.3 billion) and Novartis (valued at $1.6 billion).
The management team operates with a clear ownership mindset and an unwavering focus on long-term value creation. Although the CEO's direct ownership sits at less than 1%, his compensation is heavily weighted in equity, and his historic track record of delivering multi-billion dollar exits gives him immense credibility. The lack of red flags, combined with immediate post-IPO open-market buying from the CFO, further solidifies the team's strong alignment with retail investors.